Cargando…

Safety of cangrelor and transition to oral P2Y(12) inhibitors in patients undergoing percutaneous coronary intervention: the ARCANGELO study

AIMS: Cangrelor is the only intravenous P2Y(12) inhibitor available. Safety, efficacy, and transitioning from cangrelor to oral P2Y(12) inhibitors were recorded in patients with acute coronary syndrome (ACS). The ARCANGELO study aims to assess the safety of cangrelor on bleeding and the effects of t...

Descripción completa

Detalles Bibliográficos
Autores principales:	De Luca, Leonardo, Calabrò, Paolo, Capranzano, Piera, Di Mario, Carlo, Chirillo, Fabio, Rolfo, Cristina, Menozzi, Alberto, Menichelli, Maurizio, Bolognese, Leonardo, Musumeci, Giuseppe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10462400/ https://www.ncbi.nlm.nih.gov/pubmed/37646045 http://dx.doi.org/10.1093/ehjopen/oead076

Ejemplares similares

Use of cangrelor in patients with acute coronary syndromes undergoing percutaneous coronary intervention: Study design and interim analysis of the ARCANGELO study
por: De Luca, Leonardo, et al.
Publicado: (2022)

Feasibility and safety of cangrelor in patients with suboptimal P2Y(12) inhibition undergoing percutaneous coronary intervention: the Dutch Cangrelor registry
por: Selvarajah, Abi, et al.
Publicado: (2021)

Feasibility and safety of cangrelor in patients with suboptimal P2Y(12) inhibition undergoing percutaneous coronary intervention: rationale of the Dutch Cangrelor Registry
por: Selvarajah, A., et al.
Publicado: (2021)

Tailoring P2Y(12) Inhibiting Therapy in Elderly Patients With Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
por: Capranzano, Piera, et al.
Publicado: (2019)

Comparison of myocardial reperfusion between intracoronary versus intravenous cangrelor administration in patients undergoing primary percutaneous coronary intervention
por: Muraca, Iacopo, et al.
Publicado: (2023)

Cangrelor: Clinical Data, Contemporary Use, and Future Perspectives
por: De Luca, Leonardo, et al.
Publicado: (2021)

Ischemic Events Occur Early in Patients Undergoing Percutaneous Coronary Intervention and Are Reduced With Cangrelor: Findings From CHAMPION PHOENIX
por: Cavender, Matthew A., et al.
Publicado: (2021)

Cangrelor or Clopidogrel in Patients with Type 2 Diabetes Mellitus Undergoing Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Controlled Trials
por: Lu, Hongtao, et al.
Publicado: (2019)

Comparative effectiveness of Cangrelor in patients with acute coronary syndrome undergoing percutaneous coronary intervention: an observational investigation from the M.O.Ca. registry
por: Pepe, Martino, et al.
Publicado: (2023)

Efficacy and Safety of Cangrelor in Women Versus Men During Percutaneous Coronary Intervention: Insights From the Cangrelor versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION PHOENIX) Trial
por: O’Donoghue, Michelle L., et al.
Publicado: (2016)

Antiplatelet Therapy with Cangrelor in Patients Undergoing Surgery after Coronary Stent Implantation: A Real-World Bridging Protocol Experience
por: Rossini, Roberta, et al.
Publicado: (2020)

Efficacy of Cangrelor as Bridging Therapy Post PCI
por: Khan, Abdul A., et al.
Publicado: (2020)

Real-World Experience with Cangrelor as Adjuvant to Percutaneous Coronary Intervention: A Single-Centre Observational Study
por: Thim, Troels, et al.
Publicado: (2023)

Analysis of the Financial Impact of Using Cangrelor on the Safety and Efficacy Outcomes in Patients Undergoing Percutaneous Coronary Intervention in Whom Oral Therapy with P2Y(12) Inhibitors is Not Feasible or Desirable, in Spain
por: Lizano-Díez, Irene, et al.
Publicado: (2021)

Impact of P2Y(12)-mediated platelet reactivity on myocardial perfusion of patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a cardiac magnetic resonance study
por: La Manna, Alessio, et al.
Publicado: (2015)

The sunset of triple antithrombotic therapy for atrial fibrillation patients
por: Capranzano, Piera
Publicado: (2019)

The stent in the high-bleeding risk patient: antiplatelet monotherapy?
por: Capranzano, Piera
Publicado: (2022)

The efficacy and safety of cangrelor in single vessel vs multivessel percutaneous coronary intervention: Insights from CHAMPION PHOENIX
por: Yong, Celina M., et al.
Publicado: (2019)

P2Y(12) Receptor Function and Response to Cangrelor in Neonates With Cyanotic Congenital Heart Disease
por: Kaza, Elisabeth A., et al.
Publicado: (2017)

Cangrelor Use Patterns and Transition to Oral P2Y(12) Inhibitors Among Patients With Myocardial Infarction: Initial Results From the CAMEO Registry
por: Rymer, Jennifer A., et al.
Publicado: (2022)

Cangrelor Use in Routine Practice: A Two-Center Experience
por: van der Sangen, Niels M. R., et al.
Publicado: (2021)

Cost-Consequence Analysis of Using Cangrelor in High Angiographic Risk Percutaneous Coronary Intervention Patients: A US Hospital Perspective
por: Jensen, Ivar S., et al.
Publicado: (2021)

Timing of cardioversion in atrial fibrillation: the sooner the better?
por: Capranzano, Piera, et al.
Publicado: (2020)

Cangrelor bridging strategy for liver damage after mechanical chest compression
por: Cereda, Alberto Francesco, et al.
Publicado: (2019)

Consistent Reduction in Periprocedural Myocardial Infarction With Cangrelor as Assessed by Multiple Definitions: Findings From CHAMPION PHOENIX (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition)
por: Cavender, Matthew A., et al.
Publicado: (2016)

Late primary angioplasty (beyond 12 h): are we sure it should be avoided?
por: Bolognese, Leonardo
Publicado: (2021)

Intravenous antiplatelet therapies (glycoprotein IIb/IIIa receptor inhibitors and cangrelor) in percutaneous coronary intervention: from pharmacology to indications for clinical use
por: Capodanno, Davide, et al.
Publicado: (2019)

Antithrombotic Strategies in Patients with Atrial Fibrillation and Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention
por: De Luca, Leonardo, et al.
Publicado: (2022)

Cangrelor ameliorates CLP-induced pulmonary injury in sepsis by inhibiting GPR17
por: Luo, Qiancheng, et al.
Publicado: (2021)

Cardioprotective Properties of the Platelet P2Y(12) Receptor Inhibitor, Cangrelor: Protective in Diabetics and Reliant Upon the Presence of Blood
por: Bell, R. M., et al.
Publicado: (2015)

High Platelet Reactivity after Transition from Cangrelor to Ticagrelor in Hypothermic Cardiac Arrest Survivors with ST-Segment Elevation Myocardial Infarction
por: Buchtele, Nina, et al.
Publicado: (2020)

The effect of cangrelor and access site on ischaemic and bleeding events: insights from CHAMPION PHOENIX
por: Gutierrez, J. Antonio, et al.
Publicado: (2016)

Cangrelor Induces More Potent Platelet Inhibition without Increasing Bleeding in Resuscitated Patients
por: Prüller, Florian, et al.
Publicado: (2018)

Safety of Low Dose Intravenous Cangrelor in Acute Ischemic Stroke: A Case Series
por: Salahuddin, Hisham, et al.
Publicado: (2021)

Reply to the Letter to the Editor by D. D’Arcangelo et al.: “Ion Channels in Brain Metastasis”—Ion Channels in Cancer Set up and Metastatic Progression Ion Channels in Brain Metastasis
por: Klumpp, Lukas, et al.
Publicado: (2017)

The P2Y(12) Antagonists, 2MeSAMP and Cangrelor, Inhibit Platelet Activation through P2Y(12)/G(i)-Dependent Mechanism
por: Xiang, Binggang, et al.
Publicado: (2012)

Impact of Critical Limb Ischemia on Long-Term Cardiac Mortality in Diabetic Patients Undergoing Percutaneous Coronary Revascularization
por: Liistro, Francesco, et al.
Publicado: (2013)

Advanced pharmacodynamics of cangrelor in healthy volunteers: a dose-finding, open-label, pilot trial
por: Gelbenegger, Georg, et al.
Publicado: (2022)

Urgent Revascularization of the Left Proximal Circumflex Following Cessation of Cangrelor Within Six Hours of Procedure
por: Huang, Sherri, et al.
Publicado: (2023)

Efficacy of a Combined Antiplatelet Therapy Is Not Affected by a Simultaneous Binding of Cangrelor and PSB 0777 to Albumin
por: Wzorek, Joanna, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_aubu00r0fcbecv66am3aldh6na